NVision
NVision, founded around 2015-2016 in Ulm, Germany, develops molecular quantum technologies for cancer metabolic imaging, drug development, and quantum computing.
Position in SVTR
Snapshot 2026-10-25- Startup SignalsTop 50%↓41
- Life SciencesTop 50%↓3
- Quantum PhotonicsTop 50%↓1
About
NVision, founded around 2015-2016 in Ulm, Germany, develops molecular quantum technologies for cancer metabolic imaging, drug development, and quantum computing. Its core directions include the POLARIS metabolic MRI hyperpolarization platform and the PIQC photonic integrated quantum computing system.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2026-05Series B$38M
Investors · Playground Global, Entrée Capital, CDP Venture Capital, Matterwave Ventures, AbbottSource · SVTR Weekly #157 ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- NVision
Develops molecular quantum technology for cancer metabolic imaging, drug development and quantum computing
Series B · $120M · 2026-05
$120M
United States
BusinessLatest roundTotal raisedDateChina
BusinessLatest roundTotal raisedDateEurope
BusinessLatest roundTotal raisedDate- QuantumDiamonds
Non-destructive nanoscale current imaging of advanced chips with diamond nitrogen-vacancy (NV) center quantum sensors to detect hidden defects and improve manufacturing yield.
Series A · 2026-07
— - Q*Bird
Develops quantum cryptography technology to protect data communications from cyber threats
Undisclosed · $3M · 2024-05
$3M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 14 at a nearby stage
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.